Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central
2005-003854-80Phase 2Terminated
- Sponsor
- Department of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nuremberg
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of etoricoxib in osteoarthritis (OA), sponsored by Department of Experimental and Clinical Pharmacology and Toxicology, FAU Erlangen-Nuremberg. Primary endpoints: Change in inflammatory mediators in CSF, plasma, and tissue and Pharmacokinetics of etoricoxib in CSF, plasma, and tissue. Started Jan 2006; status: terminated.
02
Drugs
etoricoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2005-003854-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003854-80.